Behçet Disease With Vascular Involvement

AbstractVascular involvement is one of the major causes of mortality and morbidity in Behçet disease (BD). There are no controlled studies for the management of vascular BD (VBD), and according to the EULAR recommendations, only immunosuppressive (IS) agents are recommended. In this study, we aimed to investigate the therapeutic approaches chosen by Turkish physicians during the initial event and relapses of VBD and the association of different treatment options with the relapses retrospectively.Patients with BD (n = 936, female/male: 347/589, mean age: 37.6 ± 10.8) classified according to ISG criteria from 15 rheumatology centers in Turkey were included. The demographic data, clinical characteristics of the first vascular event and relapses, treatment protocols, and data about complications were acquired.VBD was observed in 27.7% (n = 260) of the patients during follow-up. In 57.3% of the VBD patients, vascular involvement was the presenting sign of the disease. After the first vascular event, ISs were given to 88.8% and AC treatment to 59.8% of the patients. Median duration of AC treatment was 13 months (1–204) and ISs, 22 months (1–204). Minor hemorrhage related to AC treatment was observed in 7 (4.7%) patients. A second vascular event developed in 32.9% (n = 86) of the patients. The vascular relapse rate was similar between patients taking only ISs and AC plus IS treatments after the first vascular event (29.1% vs 22.4%, P = 0.28) and was significantly higher in group taking only ACs than taking only ISs (91.6% vs 29.1%, P < 0.001). During follow-up, a third vascular event developed in 17 (n = 6.5%) patients. The relapse rate was also similar between the patients taking only ISs and AC plus IS treatments after second vascular event (25.3% vs 20.8%, P = 0.93). When multivariate analysis was performed, development of vascular relapse negatively correlated with only IS treatments.We did not find any additional positive effect of AC treatment used in combination with ISs in the course of vascular involvement in patients with BD. Severe complications related to AC treatment were also not detected. Our results suggest that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.

[1]  N. Sut,et al.  Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. , 2014, Rheumatology.

[2]  T. Ergun,et al.  Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers , 2014, Clinical Rheumatology.

[3]  Xuemei Li,et al.  Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients , 2013, Clinical Rheumatology.

[4]  E. Ben-Chetrit,et al.  Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. , 2012, Clinical and experimental rheumatology.

[5]  J. Piette,et al.  Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. , 2012, Arthritis and rheumatism.

[6]  Y. Ishigatsubo,et al.  Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. , 2011, Clinical and experimental rheumatology.

[7]  M. Schirmer,et al.  Major vessel involvement in Behçet's disease: an update , 2011, Current opinion in rheumatology.

[8]  Z. Amoura,et al.  Mortality in Behçet's disease. , 2010, Arthritis and rheumatism.

[9]  C. Korkmaz,et al.  Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet’s disease , 2010, Clinical Rheumatology.

[10]  A. Silman,et al.  EULAR recommendations for the management of Behçet disease , 2008, Annals of the rheumatic diseases.

[11]  E. Koh,et al.  Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation , 2008, Clinical Rheumatology.

[12]  N. Seyahi,et al.  The Long-Term Mortality and Morbidity of Behçet Syndrome: A 2-Decade Outcome Survey of 387 Patients Followed at a Dedicated Center , 2003, Medicine.

[13]  O. Ozcebe,et al.  Behçet's disease. , 2019, The New England journal of medicine.

[14]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.

[15]  E. Schulze.  [Behçet disease]. , 1958, Deutsche medizinische Wochenschrift.